uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene DezaparvovecGlobeNewsWire • 10/31/19
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company ProgressGlobeNewsWire • 10/28/19
Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark BuyoutInvestors Business Daily • 10/24/19
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia BGlobeNewsWire • 09/03/19
Uniqure Nv (QURE) CEO, CFO, Managing Director Matthew C Kapusta Sold $571,600 of SharesGuruFocus • 07/19/19
Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: AnalystInvestors Business Daily • 06/17/19
Is the Options Market Predicting a Spike in uniQure (QURE) Stock?Zacks Investment Research • 06/11/19
This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B StudyInvestors Business Daily • 05/10/19